The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and tp53 Mutations in a Zebrafish Model.

Shu-Ching Wang, Ching-Tse Wu, Dong-Yu Wu, Caleb Gon-Shen Chen, Kuo-Ming Chang, Chien-Chung Chang

Open access · goldAbstract read

In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 47% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shu-Ching WangInstitute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan.

Ching-Tse WuInstitute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan.

Dong-Yu WuInstitute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan.

Caleb Gon-Shen ChenDepartment of Hematology, Mackay Memorial Hospital, Taipei 10449, Taiwan.

Kuo-Ming ChangDepartment of Pathology and Laboratory Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu 35071, Taiwan.

Chien-Chung ChangInstitute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan. ccchang@life.nthu.edu.tw.

National Tsing Hua University · TWMackay Memorial Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST 104-2320-B-007-002, MOST 106-2320-B-007-001, MOST 107-2320-B-007-002

6 · The paper itself

Abstract

The unsatisfactory real-world efficacy of the hypomethylating agent azacitidine in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has prompted us to investigate the hematological adverse events and host variables that may compromise the use of this epigenetic drug. Using the zebrafish, we found that azacitidine destroyed their myeloid precursors and impaired myeloid function by inhibiting antigen processing, allogeneic response and phagocytic activity, resulting in increased susceptibility to infection even by the normal flora E. coli. In addition, iron overload, a MDS-associated condition following repeated transfusions, exacerbated bacterial infection especially by V. vulnificus with known iron dependence. Furthermore, we show that the tp53

Indexed as

azacitidinemyelodysplastic syndromesmyelosuppression

Identifiers

PMID31480804

DOI10.3390/cancers11091294

PMCPMC6770285

OpenAlexW2971974593

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.